IperionX Faces Pivotal Period as Key Milestone and Legal Scrutiny Converge

IperionX nears a key 2026 feasibility study for its critical minerals project, backed by U.S. funding, while facing legal probes from a reporting error that slashed its share price.

The coming weeks are set to be decisive for IperionX, as the company approaches a major operational milestone while navigating ongoing legal uncertainties. Two powerful, opposing forces are set to shape the near-term trajectory for the critical minerals developer.

Operational Momentum and Strategic Support

Operationally, the company's plans continue to advance. IperionX is targeting a significant capacity expansion to approximately 1,400 tonnes annually, a sevenfold increase over current levels, with commissioning slated for mid-2027. The business recently secured the final $4.6 million tranche of a $47.1 million U.S. Department of Defense funding award. In a further boost, the U.S. government provided IperionX with roughly 290 tonnes of titanium scrap at no cost—material equivalent to 1.5 times its current annual requirement.

Shareholders demonstrated strong backing for leadership at the Annual General Meeting on March 19, with about 95% voting in favor of long-term stock incentives for founders Anastasios Arima and Todd Hannigan. This vote of confidence comes despite the equity losing roughly 40% of its value since the start of the year.

The Forthcoming Definitive Feasibility Study

A primary catalyst on the horizon is the scheduled completion, by April 1, 2026, of the Definitive Feasibility Study (DFS) for the Titan Critical Minerals Project in Tennessee. This fully permitted project aims to produce dysprosium and terbium, rare earth elements deemed strategically critical for defense applications and high-tech manufacturing. The DFS will outline detailed project economics, production capacities, capital requirements, and the financing strategy.

Growing market interest ahead of this event was signaled on March 25, with the listing of four new options contracts on IperionX shares.

Legal Overhang from a Reporting Error

Counterbalancing the operational progress is a legal overhang stemming from a mid-March disclosure. A typographical error in the company's half-year financial statements triggered significant volatility, leading to a 27.4% decline in the share price over the two trading days following the March 13 revelation.

This event prompted investigations by several law firms, including Holzer & Holzer, into whether IperionX may have violated U.S. securities laws. These inquiries remain ongoing.

Analyst Sentiment Amid Volatility

Despite the sharp sell-off, institutional analysts maintained constructive ratings on the stock, albeit with adjusted price targets. B. Riley reaffirmed its Buy recommendation while lowering its target from $58 to $52. Similarly, Roth Capital maintained a positive outlook, adjusting its target from $74 to $71.

The confluence of the impending DFS release and the unresolved legal examinations creates a critical juncture for IperionX, with the outcomes likely to define the company's path forward in the near term.